Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess if the addition of oral ABT-751 at the recommended phase 2 dose (RPTD) of 200mg QD to standard docetaxal can prolong progression free survival (PFS) compared to docetaxal alone in subjects with advanced or metastatic NSCLC.
Critère d'inclusion
- Advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following one or more chemotherapy regimens